Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

← catalyst calendar

NCT07690436 · readout in 288 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase

—

Status

Not yet recruiting

Study type

Observational

Enrollment

500estimated

Sites

Countries

Germany, Portugal, Spain +1

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-07-02

estimated

When the study began enrolling

Primary completion

2027-06-03

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-06-03

estimated

The whole study's end, after follow-up

First posted

2026-07-08

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-08

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Transthyretin Amyloid Cardiomyopathy

Primary outcomes

what the primary-completion date above is the date OF

Comparison of per-participant confidence scores distributions between ATTR-CM cases and HF controls without ATTR-CM

measured At a single assessment time point within 90 days following informed consent form signing

Qualitative assessment of features learned indicative of ATTR pathology

measured At a single assessment time point within 90 days following informed consent form signing

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed